PYC has done it again, it filed a new patent on "Advanced...

PYC has done it again, it filed a new patent on "Advanced compositions and methods for treatment of kidney disease" on 04/04/2024. Notice the word "Advanced", which is different to the 2 previous patents for treatment of kidney disease.

Whilst PYC is already well into the tox studies on the drug for ADPKD, it is unusual to file a new patent for the same disease. One would hope that this patent is for another kidney disease.



Other Genetic Kidney Diseases

The most common causes of CKD include hypertension, diabetes mellitus, glomerular disease as well as polycystic kidney disease (PKD), which is a genetic disorder.

Apart from AKPKD (Autosomal dominant polycystic kidney disease), there is:

• ARPKD (Autosomal recessive polycystic kidney disease).

Other forms of genetic kidney disease include those with Glomerular patterns of injury such as:

• Genetic nephrotic syndrome
• Focal segmental glomerulosclerosis
• APOL1-related kidney disease
• Atypical hemolytic uremic syndrome

There are also congenital anomalies of kidneys and urinary tract (CAKUT) such as:

• Tubulointerstitial patterns of kidney disease such as autosomal dominant-tubulointerstitial kidney disease (ADTKD)

More info at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831004/

PYC's ability to discover new drugs on overdrive

This is due to 3 major factors as follows:

1. Pioneering the use of Google's Precision Drug Discovery Platform "AlphaFold" to select the best drug carrying peptide on the computer BEFORE moving forward to the 1st test tube in the lab. That would save a lot of time and wasted resources.
2. PYC's rich library of > 1.5 billion peptides which have proven to be very efficient drug carriers. High efficiency in bringing drug cargo past the cell wall into the cell = lower drug quantity = lower cost and lower toxicity.
3. Ability to build a 3D organoid using live cells from sufferers, so drugs could be tested for efficacy WELL BEFORE Phase 1 trial = high confidence!

The current SP is grossly undervaluing the company's pipeline of 4 drugs. Besides, with the capabilities above, PYC's pipeline could expand to > 8 drugs in the next 3 years. PYC is a multi-10X bagger which is a chance of a lifetime for investors! DYOR

If you find it useful, please click the Good Analysis button below